1800 244 735

Helpline (02) 9874 9777

Welcome to HDBuzz

HDBuzz is now live! Your source for Huntington’s disease research news, in plain language, written by scientists, for the global HD community. Reliable, impartial and free to share, HDBuzz will bring you solid reasons to have hope, by explaining latest news from the worldwide effort to find effective treatments for HD.

Welcome to HDBuzz

It’s our great pleasure to announce the launch of HDBuzz, a new Internet platform for the latest news about Huntington’s disease research in plain language, written by scientists who work on HD. HDBuzz is dedicated to the people who need it most – those affected by HD and their family and friends.

Huntington’s disease research news

HDBuzz will give the global HD community free access to reliable, unbiased articles that reveal and explain the amazing, cutting-edge science that’s happening in labs and clinics around the world. You can expect a story or two a week, focused on particularly exciting developments in both clinical and basic research. Also look for in-depth coverage of HD scientific conferences and other events of interest to the community.

In plain language

HDBuzz will give you access to cutting-edge science, because we believe that all scientific progress can be explained in a way that allows non-scientists to understand it – in fact, we believe that no scientific work is complete until it’s been understood by the people it concerns.

HDBuzz is an experiment, and we need to know from you how we’re doing. If an article didn’t make sense, click the ‘Didn’t understand’ button and tell us how we can improve our content. If you like an article, click the ‘enjoyed’ button to let us know.

On the hdbuzz.net site, glossary pop-ups will explain any technical terms we have to use.

Written by scientists

HDBuzz writers and editors are qualified scientists and clinicians involved in the global effort to find treatments for HD. To remain independent, writers never report on their own research, and every writer completes a ‘conflicts of interest’ statement for each article.

You can find out about the HDBuzz team via the ‘About’ section.

For the global HD community

HDBuzz is the result of an exciting collaboration between many people all over the world, and we want our content to reach as far as possible. HD knows no cultural boundaries, and neither should access to information about HD.

HDBuzz is funded by a unique consortium of HD patient organizations. Our major supporters are the Huntington’s Disease Society of America, Huntington’s Disease Association of England and Wales and the Huntington Society of Canada and we hope to welcome more global HD organizations to the consortium during 2011.

We aim to make all HDBuzz content available in as many languages as possible. We are launching in English and Spanish, and hope to add French, German and Dutch in the very near future.

Where to find us

You’ll be able to access all HDBuzz content via our web site, hdbuzz.net, and articles will also be syndicated to the HD community sites you already use – like hdsa.org, hda.org.uk and huntingtonsociety.ca where we hope they’ll provoke lively, informed debate.

HDBuzz has news feeds to the major social networking sites so you can follow HDBuzzFeed on Twitter, Facebook or Google Buzz. You can also get updates by email.

And if you have a web page or blog, you can freely use HDBuzz content automatically via RSS or reproduce specific articles you like. See our sharing page, within the about section, for full details.

Hope through knowledge

It is a very exciting time for HD research – in the coming months and years, we expect real progress towards effective treatments for this disease we’re all united to fight.

We look forward to bringing that excitement to you, and giving you solid reasons to have real hope, through HDBuzz.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Scientists identify precisely how pridopidine works in models of Huntington’s disease

Published date: 12 June, 2021

Pridopidine is a drug developed to treat Huntington’s disease (HD) and now scientists have a clearer understanding of how it works in the body and brain. In a series of academic papers, researchers figured out that pridopidine is working by targeting a particular receptor protein called S1R. With this new understanding, the researchers believe pridopidine ... Read more

Huntington's disease therapeutics conference 2021 – Day 3

Published date: 29 April, 2021

We are back for the last day of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can find with the hashtag #HDTC2021. The final session of the conference will provide the latest news on more Huntington’s disease clinical programs. A new way ... Read more

Huntington's disease therapeutics conference 2021 – Day 2

Published date: 28 April, 2021

We are back with Day 2 of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning session focussed on promising HD therapeutics that are in preclinical development and the afternoon session covered different ... Read more

Huntington’s disease therapeutics conference 2021 – Day 1

Published date: 28 April, 2021

The CHDI Therapeutics Conference 2021 kicked off today. This article summarizes our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning of Day 1 focused on clinical trial updates, while the afternoon explored genetic modifiers of HD and how they might be harnessed ... Read more

Huntington’s disease clinical trial round up

Published date: 26 April, 2021

It seems like the HD community has been inundated with updates from different companies and clinical trials recently. The news is far from complete doom and gloom; although there have been some real disappointments from some of the frontrunner trials, there are also positive updates from many different companies and lots of reasons for us ... Read more

Good news from uniQure: gene therapy trial on track, and promising data in animals

Published date: 15 April, 2021

Two recent press releases from uniQure provide welcome good news: the first ever HD gene therapy, known as AMT-130, has been administered via brain surgery to a small set of participants in an early safety trial. At the same time, uniQure has published findings in HD animal models that increase confidence in the drug’s ability ... Read more